Trial Profile
A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Methylprednisolone
- Indications Gouty arthritis
- Focus Therapeutic Use
- Acronyms ASGARD
- 05 Apr 2022 Status changed from active, no longer recruiting to completed.
- 11 Nov 2021 Planned End Date changed from 1 Sep 2021 to 31 Jan 2022.
- 11 Nov 2021 Planned primary completion date changed from 1 Sep 2021 to 31 Jan 2022.